Hey readers! Here is something that might change how you think about "I'm doing everything right but still don't feel right": a new proteomics study suggests many of us on a strict gluten-free diet still carry low-level gut inflammation that standard blood tests simply cannot see. Below we round up the healing-biomarker research worth knowing, the drug trials now enrolling, and a couple of practical wins (yes, including Canadian tax relief) you can act on today.
🔬 The healing question: what blood can and cannot tell you

How blood proteins may offer new clues to gut health in celiac disease is the study to read if you have ever wondered whether your gut has truly healed. Researchers used proteomics on 264 blood and tissue samples (collected at Rikshospitalet between 2018 and 2024), comparing untreated patients, people after one year gluten-free, and controls, and identified 24 proteins tied to celiac disease, nine of them linked to the extent of intestinal damage. - healthmedicinet
The honest and slightly uncomfortable finding: protein levels improved after a year on the diet, but some stayed elevated, pointing to residual inflammation even in diligent patients.
"Many people with celiac disease are very diligent in following the diet, but they still live with uncertainty because the blood tests do not always give clear answers about how the disease is progressing," says Jostein Holen Ibsen of the Norwegian Coeliac Disease Research Centre.
"The findings therefore suggest that patients have some inflammation in the gut even when they follow the diet," Ibsen adds.
Why it matters: standard anti-tTG IgA and total IgA monitoring loses sensitivity once you start the diet. A biomarker panel that actually tracks healing would help clinicians and patients stop guessing. It is not clinical-ready yet, but it is the direction follow-up care needs to go.
A continuous composite endpoint methodology improves statistical efficiency tackles the same problem from the trial-design side. Instead of judging recovery by one marker at a time, this BMC Medicine proof-of-concept combines histologic, immunologic, and serologic biomarkers onto one scale. - BMC Medicine
Tested across a 14-day gluten challenge and a 52-week recovery study, the composite increased effect sizes (the histologic VCIEL composite lifted Cohen's d from 1.92 and 1.85 for its parts up to 2.30) and, in simulations, cut the sample size needed for 80% power from 90 to 45 with four biomarkers. The gains shrank when markers were highly correlated or when one dominated. For patients, the payoff is practical: more efficient trials mean faster, cheaper answers about whether a treatment actually heals the gut.
Blood may reveal signs of gut-related disease that stool samples miss adds another blood-based angle. Serum short-chain fatty acid profiles hit 95% accuracy distinguishing celiac, colorectal cancer, and obesity from healthy controls, versus just 59% for stool-based profiles. - News-Medical
Valeric, propionic, isovaleric, and 2-methylbutyric acids did most of the work. Blood and stool turned out to carry complementary, not redundant, information. Early-stage and cohort-limited, but it reinforces the theme running through this issue: your bloodstream may hold healing signals we have not been reading.
💊 Drugs aiming to protect the gut (and trials enrolling now)

New Phase 2 Trial Tests ZED1227 for Celiac Disease is a concrete click target if you still have symptoms despite a year or more gluten-free. The CEC-013 study is enrolling in the US and Europe, aiming for 356 participants ages 18 to 80. - BeyondCeliac.org
ZED1227 (from Dr. Falk Pharma and Takeda) blocks transglutaminase 2, the enzyme that makes gluten fragments more visible to inflammatory cells. The 15-week design includes gluten-containing study granola bars, two endoscopies with biopsy, and symptom diaries, so this is a real commitment, not a questionnaire. A prior Phase 2a showed protective effects on the intestinal lining during a six-week gluten challenge
Teva's Celiac Drug Becomes First to Block Gluten Damage in Clinical Trial reports on TEV-'408, an anti-IL-15 antibody. In a randomized, double-blind Phase 2a (n=50) with an eight-week gluten challenge, Teva says it hit the primary histological endpoint (Vh:Cd ratio) with a larger effect on IEL density. - Tech Times
The key mechanism: cells lining the small intestine overproduce interleukin-15 (IL-15), a cytokine that normally helps coordinate immune responses.
Teva's stronger claims deserve a grain of salt, but a separate writeup confirms the drug met its primary endpoint, with Phase 2b expected in the second half of 2027.
First Tracks Biotherapeutics at Jefferies: celiac data lifts outlook rounds out the pipeline. On November 16, the company reported ANB033 showed a 0.49 delta on villus height to crypt depth ratio versus placebo and a 98% reduction in IELs during a 14-day gluten challenge, with no symptom increase. - Investing.com
Most relevant to the healing theme: an ongoing Cohort 2 is designed to measure recovery without a gluten challenge, with results expected in the first quarter of 2027.
🧒 Screening, terminology, and the bigger picture

Harmonizing scientific terms and concepts in early celiac disease may sound like housekeeping, but it underpins everything above. A review in Gut from Karolinska Institutet and the Mayo Clinic, with 22 scientists across seven countries, standardizes the vocabulary of early disease after the B4CeD task force reviewed 2,623 publications. - Karolinska Institutet
"We hope that consistent use of terms and concepts will facilitate comparison of research findings, increase translatability into clinical practice and improve clinical guidelines," says first author Jonas F. Ludvigsson.
Shared definitions are what let biomarker and trial results actually be compared across studies.
A few more worth a quick look:
Childhood screening for type 1 diabetes and coeliac disease proved feasible in Italian pilot: the D1Ce Screen pilot enrolled 5,535 children, with samples adequate for autoantibody testing in 89.4% and over 80% of clinicians calling it very useful medically. Feasibility, not yet proof it improves long-term outcomes.
Italy's national pediatric screening decree takes effect April 8, 2027 for a cohort of young children, with voluntary participation; a related confirmation cites a spring 2027 start under Law 130 of 2023. Note for parents: a positive antibody result is not a diagnosis, and do not change the diet before confirmatory testing.
Baby D1Ce has screened nearly 2,500 children ages 1 to 5, with about 100 autoantibody-positive referrals, extending screening to a younger group.
Poland's Ministry of Health confirmed NFZ-funded anti-tTG IgA and IgG testing from January 1, 2027, against an average diagnostic delay of 7 years (9 in adults, 3.1 in children).
🧠 Living with celiac: the parts tests don't capture

Celiac Disease Linked to a 39% Higher Risk of Eating Disorders is important reading for clinicians and families. In a Swedish study of 37,853 biopsy-confirmed patients, the adjusted hazard ratio for an eating disorder was 1.39, concentrated in the first five years after diagnosis. - Twikup
No excess risk appeared in biological parents, siblings, or children, which points to the burden of living with the condition rather than shared genetics. Absolute risk stays low (about one extra case per 222 people over 20 years), but the first strict, all-consuming years deserve gentle attention.
Exploring the link between personality traits and the gluten free diet in adolescents pairs well with that. In 50 adolescents aged 14 to 17, lower conscientiousness tracked with poorer diet adherence and higher neuroticism with more anxiety and depressive symptoms. - Coeliac UK
It is small and exploratory, but it supports tailoring dietary counselling to the actual teenager in front of you rather than one script for everyone.
On the practical side, two wins for day-to-day life. Celiac Canada applauds Budget 2026 tax relief and VOCM's coverage both report that, starting with the 2026 tax year, Canadians with a diagnosis can claim an optional flat $1,000 under the Medical Expense Tax Credit (with a certified medical letter) instead of saving every receipt, meaningful when gluten-free bread can run upwards of $9 a loaf.
And for eating out or traveling safely, Find Me Gluten Free (https://www.findmeglutenfree.com/) remains a genuinely handy site and app for scoping safe restaurants and groceries. We are not sponsored by them; it is just a tool our readers keep finding useful.
Take care of your gut and yourselves. We will keep watching the healing-biomarker research so you do not have to.
